Diabetes Drug Under Review: US

Regulators said that experts are re-examining a clinical trial of the GlaxoSmithKline diabetes drug Avandia, restricted in the US and banned in Europe amid concerns it raises heart attack risk.

The purpose is to vote on whether the restrictions should be amended.

$3bn Fine for GlaxoSmithKline In US
US authorities fined GlaxoSmithKline with $3 billion by Monday over accusations that it marketed drugs for unauthorized uses, withheld safety data, and defrauded the government's Medicaid program.

The Food and Drug Administration said a 28-member panel is to rule on a new analysis of the results of a GSK trial called RECORD, which confirmed the company's initial finding that Avandia does not raise cardiac risk any more than other diabetes drugs on the market.

GSK recently paid researchers at Duke University in North Carolina to carry out this new analysis of the data.

FDA experts said this week on the agency's web site that "overall it appears that Duke's readjudication procedures and execution were rigorous." A readjudication is an independent review.

Rise in GlaxoSmithKline Profits
In the first quarter net profit of GlaxoSmithKline rose 14 percent to ï¿½1.525 billion.

"Overall, the readjudication supports the previous observation that, in this trial, rosiglitazone was not associated with increased all-cause mortality or increased cardiovascular mortality," they said, referring to the active ingredient in Avandia.

The experts thus endorsed the re-evaluation done at Duke and, in effect, the conclusion expressed by GSK.

GlaxoSmithKline for Malaria Vaccine�s Clinical Trials in Africa Next Year
The final clinical trials for an anti-malaria vaccine are set to begin in January in seven African countries, officials from pharmaceutical giant GlaxoSmithKline said on Tuesday.

In 2010, the FDA slapped tight restrictions on use of Avandia, following the recommendations of independent experts who had concluded the drug significantly raised the risk of heart attacks.

Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, wrote on her blog that the meeting of experts Wednesday and Thursday is justified by public interest in Avandia and "the continued uncertainty of the risk surrounding this drug."

GlaxoSmithKline Urges Kenya to Crackdown on Imports of Fake Medicines
British pharmaceuticals giant GlaxoSmithKline, urged the Kenyan government on Monday to block imports of fake medicines, that account for a third of the country's drugs trade.

"FDA is holding this meeting to have a transparent, public discussion with experts across multiple scientific disciplines on the results of the readjudication of the study," Woodcock wrote.

The experts are to vote Thursday on whether the restrictions imposed on Avandia should be modified or not.

Source-AFP